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STATE-OF-THE-ART PAPER STATE-OF-THE-ART PAPER875The Potential Risks of Long-Term Statin TherapyJ. Wouter Jukema, Christopher P. Cannon, Anton J. M. de Craen, Rudi G. J. Westendorp, Stella Trompet
The debate whether statins, 3-hydroxymethyl-3-methylglutaryl coenzyme A reductase
inhibitors, have significant detrimental effects has been ongoing since their introduction in
1987. Individual specific rare adverse events have been reported, such as myopathies, elevation
in liver enzymes, diarrhea, and very rarely rhabdomyolysis, which resolve with discontinuation.
The debate regarding the possible negative long-term effects of statin treatment on cognitive
function, cancer, and diabetes mellitus is still not settled. In this review, Jukema and
colleagues discuss all evidence, from case reports to large randomized controlled clinical trials,
for the possible adverse effects of statin use on cognitive decline, cancer and diabetes mellitus
type 2. They conclude that there is no increased risk of cognitive decline or cancer with statin
use, but there is an increased risk of new onset diabetes.CLINICAL RESEARCH INTERVENTIONAL CARDIOLOGY882Higher Mortality for Men Versus Women After TAVRKarin H. Humphries, Stefan Toggweiler, Josep Rodés-Cabau, Luis Nombela-Franco, Eric Dumont,
David A. Wood, Alexander B. Willson, Ronald K. Binder, Melanie Freeman, May K. Lee, Min Gao,
Mona Izadnegahdar, Jian Ye, Anson Cheung, John G. Webb
In the PARTNER 1A trial women derived greater benefit of transcatheter aortic valve
replacement (TAVR) over surgery than men, but whether this was due to women’s poorer
surgical outcomes or better TAVR outcomes is unknown. Humphries and colleagues
reviewed outcomes from 641 consecutive patients undergoing TAVR at 2 large centers.
Females had more major vascular complications but lower mortality. The adjusted odds ratio
for 30-day all-cause mortality favored women, 0.39, and this benefit persisted for 2 years
(hazard ratio: 0.60). These results suggest TAVR may be the preferred treatment option for
elderly females with aortic stenosis.(continued on page A-18)
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pISCHEMIC HEART DISEASE887Ramipril Ameliorates Platelet Resistance to Nitric OxideScott R. Willoughby, Sharmalar Rajendran, Wai P. Chan, Nathan Procter, Sue Leslie, Elizabeth A. Liberts,
Tamila Heresztyn, Yuliy Y. Chirkov, John D. Horowitz
Ramipril prevents cardiovascular events but the mechanism in unclear. Nitric oxide (NO)
resistance at both platelet and vascular levels is present in a substantial proportion of patients
with diabetes and/or ischemic heart disease. Horowitz and colleagues performed a double-
blind, randomized comparison of ramipril with placebo in patients similar to those
enrolled in the HOPE trial and found ramipril increased platelet responsiveness to
NO, in patients with impaired baseline NO responsiveness. In a second study of
subjects with impaired platelet NO responsiveness, the mechanism for this
improvement correlated directly with increased NO-stimulated platelet generation of
cyclic guanosine monophosphate. Ameliorating platelet NO resistance appears to be
one of the mechanisms by which ramipril prevents cardiovascular events.Editorial Comment: Dominick J. Angiolillo, Davide Capodanno, p. 895ISCHEMIC HEART DISEASE
898drenergic Pathway Polymorphisms Are Associated With Mortality
in ACS Patients Treated With Beta-Blockers in a Race-Specific MannerSharon Cresci, Gerald W. Dorn II, Philip G. Jones, Amber L. Beitelshees, Allie Y. Li, Petra A. Lenzini,
Michael A. Province, John A. Spertus, David E. Lanfear
Genetic polymorphisms in the adrenergic pathway may explain some of the racial disparities
seen in cardiovascular diseases treated with -adrenergic receptor blockade. In a prospective
ohort of 2,673 acute coronary syndromes (ACS) patients discharged on -adrenergic
eceptor blockade, subjects were genotyped for polymorphisms in ADRB1, ADRB2,
DRA2C, and GRK5. The overall 2-year mortality rate was 7.5% for Caucasians and 16.7%
or African Americans. In Caucasians, ADRA2C 322-325 deletion carriers had significantly
ower mortality as compared with individuals lacking the deletion. In African Americans, the
DRB2 16R allele was associated with significantly increased mortality. Adrenergic pathway
olymorphisms may affect post-ACS outcomes in a race-specific manner.(continued on page A-19)
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908igh Risk of Repeat Arrhythmias in Patients With
Vasospastic Angina and Previous Lethal Ventricular ArrhythmiaYuya Matsue, Makoto Suzuki, Mitsuhiro Nishizaki, Rintaro Hojo, Yuji Hashimoto, Harumizu Sakurada
The prognosis of patients with vasospastic angina (VSA) is known to be good with
medication; however, fatal ventricular arrhythmias do occur. Matsue and colleagues reviewed
data from a cohort of patients who presented with a lethal ventricular arrhythmia and were
found to have a structurally normal heart and VSA as the likely etiology of their cardiac
arrest. Twenty-three such patients had an implantable cardioverter-defibrillator (ICD) placed
and were followed for a median of 2.1 years. During follow-up, one-quarter of the patients
had a subsequent lethal arrhythmia. There were no statistically significant differences in
patient characteristics between the recurrence and nonrecurrence groups, to identify those at
higher risk. Patients with VSA and lethal ventricular arrhythmia are a high-risk population
for recurrence even medical therapy.Editorial Comment: L. Brent Mitchell, p. 914HEART RHYTHM DISORDERS917Population-Based Registry Data Suggest a Genetic Cause for Lone AFNina Øyen, Mattis F. Ranthe, Lisbeth Carstensen, Heather A. Boyd, Morten S. Olesen, Søren-Peter Olesen,
Jan Wohlfahrt, Mads Melbye
Øyen and colleagues investigated whether an individual’s risk of developing lone atrial
fibrillation (AF) before age 60 years is associated with lone AF in relatives. Using Danish
national registers, 9,507 persons with lone AF were identified. Subjects with a preceding
cardiovascular/endocrine diagnosis were excluded. The incidence rate ratios (IRRs) for lone
AF given an affected first- or second-degree relative were 3.48 and 1.64, respectively. For
subjects with at least 2 first degree-relatives affected with lone AF, the IRR was 6.24. A
family history of lone AF is associated with a substantial risk of lone AF suggesting a genetic
cause for this disorder.(continued on page A-20)
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ECARDIAC IMAGING922Progression of Myocardial Fibrosis in Patients With HCMGiancarlo Todiere, Giovanni Donato Aquaro, Paolo Piaggi, Francesco Formisano, Andrea Barison,
Piergiorgio Masci, Elisabetta Strata, Lorenzo Bacigalupo, Mario Marzilli, Alessandro Pingitore,
Massimo Lombardi
In patients with hypertrophic cardiomyopathy (HCM), myocardial fibrosis, detected by late
gadolinium enhancement (LGE) with cardiac magnetic resonance (CMR) imaging, is
associated with progressive ventricular dysfunction and worse prognosis. Todiere and
colleagues compared serial examinations approximately 2 years apart to quantify the
progression of fibrosis. At CMR-1, LGE was detected in 82% of subjects, with a mean
extent of 13.3 g. At CMR-2, 96% of patients had LGE, with an extent of 24.6 g. LGE
extent increased significantly (1 g) in 80% of patients, with a higher increment in patients
ith apical hypertrophy than other patterns. These results demonstrate the progressive nature
f myocardial fibrosis in patients with HCM.ditorial Comment: David A. Bluemke, Eunice Yang, p. 930YEAR IN CARDIOLOGY SERIES YEAR IN CARDIOLOGY SERIES932The Year in AtherothrombosisJavier Sanz, Pedro R. Moreno, Valentin Fuster
Sanz and colleagues review the literature related to the broad field of atherothrombosis.
Highlights include increasing evidence of links between vascular disease, aging, and
degenerative brain disease, and the use of coronary calcification as the most powerful
noninvasive predictor of cardiovascular outcomes. Policies to promote cardiovascular health
and medication affordability/adherence may have a large impact on cardiovascular disease
(CVD) control. Also covered is the failure of extended-release niacin to improve outcomes in
established CVD patients on statins, and more evidence that moderate (vs. intensive) blood
pressure and glucose control for patients with diabetes is optimal.
